Picture loading failed.

Anti-IFNG therapeutic antibody (Pre-made Fontolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-219-1mg 1mg 3090
GMP-Bios-ab-219-10mg 10mg 21890
GMP-Bios-ab-219-100mg 100mg 148000
GMP-Bios-ab-219-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IFNG therapeutic antibody (Pre-made Fontolizumab biosimilar,Whole mAb)
INN Name Fontolizumab
TargetIFNG
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure1t3f:BA/1t04:DC:BA
95-98% SI StructureNone
Year Proposed2002
Year Recommended2003
CompaniesPDL BioPharma
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis
Development Techna